Needham & Company cut shares of Sarepta Therapeutic (NASDAQ:SRPT) from a buy rating to a hold rating in a report issued on Tuesday morning, TheFlyOnTheWall.com reports.
Shares of Sarepta Therapeutic (NASDAQ:SRPT) traded down 3.33% on Tuesday, hitting $12.72. The stock had a trading volume of 8,634,765 shares. Sarepta Therapeutic has a 52 week low of $12.35 and a 52 week high of $55.61. The stock’s 50-day moving average is $42.96 and its 200-day moving average is $38.6. The company’s market cap is $426.5 million.
Sarepta Therapeutic (NASDAQ:SRPT) last released its earnings data on Tuesday, November 12th. The company reported ($0.63) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.65) by $0.02. The company had revenue of $4.20 million for the quarter, compared to the consensus estimate of $4.57 million. During the same quarter last year, the company posted ($2.17) earnings per share. Sarepta Therapeutic’s revenue was down 44.7% compared to the same quarter last year. On average, analysts predict that Sarepta Therapeutic will post $-3.46 earnings per share for the current fiscal year.
A number of other firms have also recently commented on SRPT. Analysts at Piper Jaffray Cos. downgraded shares of Sarepta Therapeutic from an overweight rating to an underweight rating in a research note to investors on Tuesday. They now have a $20.00 price target on the stock, down previously from $58.00. Separately, analysts at FBR & Co. initiated coverage on shares of Sarepta Therapeutic in a research note to investors on Wednesday, October 30th. They set a market perform rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Sarepta Therapeutic in a research note to investors on Wednesday, October 30th. They set a market perform rating and a $48.00 price target on the stock. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $35.74.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.